secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2023-08-21T23:59:59+00:00
Accession:  0001213900-23-069142
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals Q2 net income $1.1M; plans two Phase 3 trials for AD04
----------------------------------------------------------------------------

- Net income of $1.1M vs net loss of $3.8M in Q2 2022; includes $2.66M gain from Purnovate sale.
- Cash and equivalents $1.2M at June 30, 2023, down from $4.0M at Dec 31, 2022; runway into Q1 2024.
- Sale of Purnovate subsidiary reduces cash burn; Adial received $450K upfront, up to $83M in milestones plus 19.9% equity stake in Adovate.
- FDA confirmed primary endpoint (Percentage No Heavy Drinking Days) for AD04; planning two parallel Phase 3 trials.
- R&D expense down 37%, G&A down 59% YoY due to lower trial activities and cost reductions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023069142/0001213900-23-069142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023069142/ea183948-8k_adialpharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-069142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer